PMID- 22629830
OWN - NLM
STAT- MEDLINE
DCOM- 20120622
LR  - 20151119
IS  - 0507-3758 (Print)
IS  - 0507-3758 (Linking)
VI  - 58
IP  - 1
DP  - 2012
TI  - [The optimal radiation volume after first-line chemotherapy in Hodgkin lymphoma].
PG  - 61-5
AB  - Radiation therapy has evolved from extended-field radiation therapy (EFRT) to 
      involved-field radiation therapy (IFRT), reducing toxicity while maintaining high 
      cure rates. Recent publications recommend a further reduction to involved-nodal 
      radiation therapy (INRT); however, this has not been clinically validated. The 
      need for irradiation or optimal radiation volume after chemotherapy are not 
      defined. The treatment results of 296 Hodgkin's disease patients receiving ABVD 
      or BEACOPP-21 chemotherapy with consequent EFRT demonstrate CR/PR > or = 80% and 
      99% local disease control rate. Beam therapy with EFRT is possible to use if dose 
      levels don't exceed 30 Gy. Higher doses demands reduction of volume of radiating 
      target. In our opinion the optimum program of beam therapy involves 2 stages with 
      maximal possible dose level EFRT followed by additional INRT. Those approaches 
      offer perspectives for Hodgkin's disease treatment.
FAU - Ivashin, A V
AU  - Ivashin AV
FAU - Datsenko, P V
AU  - Datsenko PV
FAU - Pan'shin, G A
AU  - Pan'shin GA
FAU - Sotnikov, V M
AU  - Sotnikov VM
FAU - Gombolevskii, V A
AU  - Gombolevskii VA
FAU - Golub, S V
AU  - Golub SV
FAU - Evstikheev, E V
AU  - Evstikheev EV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vopr Onkol
JT  - Voprosy onkologii
JID - 0413775
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - ABVD protocol
RN  - BEACOPP protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Dacarbazine/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Hodgkin Disease/*drug therapy/mortality/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prednisone/administration & dosage
MH  - Procarbazine/administration & dosage
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Adjuvant/methods
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage
MH  - Vincristine/administration & dosage
EDAT- 2012/05/29 06:00
MHDA- 2012/06/23 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2012/06/23 06:00 [medline]
PST - ppublish
SO  - Vopr Onkol. 2012;58(1):61-5.